EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudie

Methylprednisolone pulse and prednisolone for intensification of primary treatment in Kawasaki disease patients at high risk of treatment resistance: a multicenter prospective cohort study

Masaru Miura, Koichi Miyata, Tetsuji Kaneko, Shogo Akahoshi, Yoshihiko Morikawa, Takahiro Matsushima, Hiroshi Sakakibara, Tohru Kobayashi, Takahiro Nakamura, Tsutomu Takahashi, Maki Nakazawa, Akimichi Shibata und 1 weitere

European Journal of Pediatrics · 2024

DOI: 10.1007/s00431-024-05689-y ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Pediatrics, 2024. Verfasst von Masaru Miura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai Fuchu, Tokyo, 183-8561, Japan. masaru10miura@gmail.com. Hauptthemen laut MEDLINE: Glucocorticoids, Immunoglobulins, Intravenous, Methylprednisolone, Mucocutaneous Lymph Node Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Tokyo Metropolitan Hospitals in Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study is to determine whether adding intravenous methylprednisolone pulse (IVMP) to primary adjunctive prednisolone with intravenous immunoglobulin (IVIG) improves treatment resistance and coronary artery aneurysms (CAA) in patients with Kawasaki disease (KD) with a high risk of treatment resistance. This multicenter, prospective, observational study was conducted at 28 hospitals in Japan from October 2016 to June 2020. For patients predicted to be resistant to treatment based on a Kobayashi score ≥ 5 and total bilirubin ≥ 1.0 mg/dL, each hospital independently decided to add IVMP followed by prednisolone, prednisolone alone, or nothing to the primary IVIG therapy. In total, 2856 consecutive KD patients were enrolled; of these, 399 (14.0%) were predicted to be treatment resistant. Patients who were resistant to the primary treatment and required additional treatment comprised 59%, 20%, and 26% of the IVIG-alone group, IVIG-plus-prednisolone group, and IVIG-plus-IVMP group, respectively (P < .0001). The CAA incidence (Z score ≥ 2.5) at month 1 was similar among the treatment groups (6.7%, 4.8%, and 7.3%, respectively; P = .66). CAA occurred more frequently in patients who needed third- or later-line therapy.

Conclusions

Primary adjunctive corticosteroid therapy improved the treatment response and suppressed inflammation. However, the study found no benefit of adding IVMP to prednisolone therapy. Patients receiving IVIG alone achieved coronary outcomes comparable to those of patients receiving primary adjunctive corticosteroid therapy although they were more likely to require additional rescue treatment. KD inflammation should be resolved no later than the third line of additional treatment to reduce the risk of CAA.

Trial registration

University Hospital Medical Information Network Clinical Trials Registry in Japan ( https://www.umin.ac.jp/ctr/index.htm ) under code UMIN000024937.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucocorticoidsImmunoglobulins, IntravenousMethylprednisoloneMucocutaneous Lymph Node SyndromePrednisoloneChild, PreschoolFemaleHumansInfantMaleCoronary AneurysmDrug ResistanceDrug Therapy, CombinationImmunologic FactorsJapanProspective StudiesPulse Therapy, DrugTreatment Outcome

Stichwörter der Autor:innen

Coronary artery aneurysmsCorticosteroidKawasaki diseaseTreatment resistance

Substanzen

GlucocorticoidsImmunoglobulins, IntravenousImmunologic FactorsMethylprednisolonePrednisolone

Autor:innen und Institutionen

  • Department of Cardiology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai Fuchu, Tokyo, 183-8561, Japan. masaru10miura@gmail.com.
  • Department of Cardiology, Tokyo Metropolitan Children's Medical Center, 2-8-29 Musashidai Fuchu, Tokyo, 183-8561, Japan.
  • Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
  • Teikyo Academic Research Center, Teikyo University, Tokyo, Japan.
  • Department of General Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
  • Department of Data Science, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.

Förderung

  • Tokyo Metropolitan Hospitals in Japan

Zitieren

APA

Miura, M., Miyata, K., Kaneko, T., Akahoshi, S., Morikawa, Y., Matsushima, T., Sakakibara, H., Kobayashi, T., Nakamura, T., Takahashi, T., Nakazawa, M., Shibata, A., & Yamagishi, H. (2024). Methylprednisolone pulse and prednisolone for intensification of primary treatment in Kawasaki disease patients at high risk of treatment resistance: a multicenter prospective cohort study. European Journal of Pediatrics. https://doi.org/10.1007/s00431-024-05689-y

Vancouver

Miura M, Miyata K, Kaneko T, Akahoshi S, Morikawa Y, Matsushima T, et al. Methylprednisolone pulse and prednisolone for intensification of primary treatment in Kawasaki disease patients at high risk of treatment resistance: a multicenter prospective cohort study. European Journal of Pediatrics. 2024. doi:10.1007/s00431-024-05689-y

BibTeX
@article{Miura2024,
  author = {Miura, Masaru and Miyata, Koichi and Kaneko, Tetsuji and Akahoshi, Shogo and Morikawa, Yoshihiko and Matsushima, Takahiro and Sakakibara, Hiroshi and Kobayashi, Tohru and Nakamura, Takahiro and Takahashi, Tsutomu and Nakazawa, Maki and Shibata, Akimichi and Yamagishi, Hiroyuki},
  title = {Methylprednisolone pulse and prednisolone for intensification of primary treatment in Kawasaki disease patients at high risk of treatment resistance: a multicenter prospective cohort study},
  journal = {European Journal of Pediatrics},
  year = {2024},
  doi = {10.1007/s00431-024-05689-y}
}
Kostenlos starten →